I would appreciate people's thoughts on a methodology consideration.

We're docking several thousand small molecules at a specific location on the receptor. We're using Autodoc Vina to reduce the library to e.g., 20 compounds. Then, further reduction follows using generalised Born and surface area solvation (MM/GBSA), etc.

This is my concern. The crystal structure is a substrate-bound enzyme. Those that prepared the structure mutated Glu to Gln to prevent activation. This single-point mutation is far from where we are docking the compounds e.g., > 4 nanometres. We are considering what our risks and limitation in our study are before running anything. Will an in silico modification (reverting from Gln to Glu) in the crystal structure affect calculation performed by Autodock (vina of AD4) if those changes are outside the grid box in which docking calculations are performed?

I understand the calculations performed by Adutodock/Vina are stochastic to a degree, so a direct comparison of how that mutation affects the results would be tough to produce. However, is there any merit in performing a before and after screening on the receptor, even if that change is far from the docking site?

More Anthony Nash's questions See All
Similar questions and discussions